Promising treatments in oncology : Gustave Roussy is at the ESMO TAT congress

The ESMO Targeted Anticancer Therapies (TAT) congress, organized annually in Europe since 2018, is a major event in promising new targets and new agents in oncology, mostly the ones in early trials of clinical development.

Its 2024 edition, which occurs from February 26 to February 28 in Paris, is an opportunity to have an overview of the future of innovating treatments and early trials currently run globally. The ESMO TAT congress also allows academics and industrials to exchange on the latest breakthroughs in oncology.

This year, the discussions will focus on innovations in phase I trials, with breakthroughs in target and cell therapies, in immunotherapy, and molecular imagery. Discussions will also focus on methodological and regulatory issues.

Strong representation of Gustave Roussy and its early trials department

Gustave Roussy, strongly committed to phase I clinical trials through its Department of Therapeutic Innovations and Early Trials (DITEP), actually run by Christophe Massard, MD, PhD, has historically played a role in the creation of ESMO TAT congresses.

Gustave Roussy’s DITEP is one of the biggest early trials centers in Europe and in the world. In 2023, 2 700 patients have been screened, and 450 are dosed in Phase I and Phase I-II every year. At the same time, more than 140 protocols are currently run and 10,000 patients have been or are enrolled in a precision medicine program.

During this 2024 edition, several of the Institute's physician-researchers are taking the floor to talk about the research and clinical trials carried out at Gustave Roussy.

• Fabrice André, MD, Ph.D., head of the research at Gustave Roussy, moderates a discussion on the challenges of the new regulations in Europe.
• Antoine Italiano, MD, PhD, head of the precision medicine program at Gustave Roussy, provides an update on the new pI3KCA inhibitors.
• Sophie Postel-Vinay, MD, PhD, head of the EpiCure SIRIC, is a member of the scientific committee of TAT. She is a moderator during the session “Diving into hepatobiliary malignancies”.
• Capucine Bladini, MD, an oncologist at the DITEP, talks about new EGFR/HER2 inhibitors and puts the results of two studies on new immunotherapies into perspective.
• Antoine Hollebecque, MD, an oncologist at the DITEP, gives his perspective on the immunotherapies in liver cancers.
• Barbara Pistilli, MD, head of the breast diseases committee at Gustave Roussy, presents the latest developments in conjugate antibodies in oncology.